Navigation Links
Inverseon Announces Positive Phase IIa Asthma Study

SAN FRANCISCO, Jan. 29 /PRNewswire/ -- Inverseon, Inc. ( announces the publication of a positive phase IIa clinical trial in asthma.

In the article by Hanania et al., in Pulmonary Pharmacology & Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study," mild asthmatics were treated for 9 weeks. All subjects tolerated the drug, and 8 of 10 subjects experienced a clinically meaningful, dose-related, reduction in airway hyper-responsiveness.

"To our knowledge, this is the first peer-reviewed publication of a clinical trial testing a beta-blocker for the treatment of asthma," commented Richard Bond, PhD, Scientific Founder of Inverseon. "These results lay the groundwork for continuing safety and efficacy studies for a drug that is normally withheld from asthmatics. A similar story played out 10 years ago in congestive heart failure where certain blocker drugs that were once contraindicated are now on the market as the best drugs we have ever had at decreasing mortality in heart failure."

"From receptor theory to animal data and now to clinical data the Inverseon approach is very consistent. In our animal asthma models chronic dosing of beta inverse agonists -- which are a subset of beta blockers -- resulted in up-regulation of lung beta receptors, while reducing inflammation and airway hyper-responsiveness. The fact that we are seeing some of these same changes in human asthmatic subjects is exciting and suggests we may have a way to counteract some of the negative aspects of long-acting beta-agonists and steroids when used in combination with INV102. The data also supports Inverseon's reformulation program for oral controlled-release INV102," commented William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.


William J. Garner, MD

(212) 222-1188

This release was issued through eReleases(TM). For more information, visit

SOURCE Inverseon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
3. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
4. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
5. InterCure Announces 100,000th RESPeRATE Unit Sold
6. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):